Eli Lilly presented new clinical trial results on June 7 in New Orleans, highlighting the effects of its newly approved oral drug Foundayo and investigational triple agonist retatrutide in weight loss and related health conditions. The presentations took place during the American Diabetes Association Scientific Sessions.
The company shared findings from multiple studies of retatrutide, including results from the Phase 3 TRIUMPH-1 trial. Patients who took retatrutide achieved a 28.3% reduction in body weight—equivalent to 70 pounds—at 80 weeks. Additional benefits included a 73% reduction in osteoarthritis knee pain and a 60% decrease in moderate-to-severe sleep apnea severity, representing a reduction of 36 events per hour.
In another study, the Phase 3 TRANSCEND-T2D-1 trial involving patients with diabetes, those taking retatrutide saw A1C reductions of up to 2%, with an average weight loss of 36.6 pounds or 16.8% at week 40. Nearly half of these patients achieved normal A1C levels.
Kenneth Custer, president of Lilly Cardiometabolic Health, said in a June 6 news release, “By addressing weight, glycemia and obesity-related complications together, these results highlight retatrutide’s potential across the cardiometabolic spectrum and reinforce our commitment to delivering options that meet patients’ needs and preferences.”
Lead trial investigator Ania Jastreboff from Yale School of Medicine said, “Obesity drives more than 200 downstream diseases, yet we have historically treated those conditions one at a time and in silos. These findings demonstrate what may be possible when we treat obesity and impact overall health, and what this could mean for people living with obesity and its related complications.”
Lilly also reported new data on Foundayo from the Phase 3 ATTAIN program. Women across all stages of menopause lost significant amounts of weight by week 72; women in perimenopause lost up to 30.4 pounds (14.4% body weight), while postmenopausal participants lost an average of 28.2 pounds (14.1%). In ATTAIN-2—which focused on women with diabetes experiencing menopause—similar levels of weight loss were observed.
Rachel Batterham, senior vice president at Lilly for medical innovation and external engagement, said, “For women who have seen their weight become harder to manage precisely when their health is more at risk, this is what progress could look like.”
Lilly plans to present additional data from its diabetes and obesity pipeline—including longer-term data for Mounjaro—at upcoming sessions during the ADA meeting.
